Thus, if we can inhibit mesothelial conversion to OCAMs or inhibit the FN1/Akt signaling pathway axis, we may be able to effectively control the development of peritoneal metastatic tumors even with the use of conventional platinum‐based chemotherapy. This evidence concerns the gene AKT1 and metastatic neoplasm.